https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
In conclusion, expression of FOXD4 may be a diagnostic and prognostic biomarker in COAD.We investigated the clinicopathologic features, immunophenotype, (differential) diagnosis, pathogenesis, treatment, and follow-up of medullary thyroid carcinoma (MTC) combined with papillary thyroid carcinoma (PTC). A retrospective analysis of the clinical and pathologic features and immunophenotype was conducted in a patient with MTC and PTC. Relevant literature was also reviewed. Results of thyroid fine needle aspiration indicated
Like
Comment
Share
